Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) EPS (Weighted Average and Diluted) (2021 - 2026)

Rani Therapeutics Holdings' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.04 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 81.82% to -$0.04 in Q1 2026 year-over-year; TTM through Mar 2026 was -$0.29, a 70.71% increase, with the full-year FY2025 number at -$0.45, up 57.14% from a year prior.
  • EPS (Weighted Average and Diluted) came in at -$0.04 for Q1 2026, down from $0.05 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.33 in Q3 2022, with the low at -$2.21 in Q4 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.25 across 5 years, with a median of -$0.24 in 2024.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 306.25% in 2022, while the deepest fall reached 718.52% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$2.21 in 2022, then surged by 87.78% to -$0.27 in 2023, then changed by 0.0% to -$0.27 in 2024, then skyrocketed by 118.52% to $0.05 in 2025, then plummeted by 180.0% to -$0.04 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for RANI at -$0.04 in Q1 2026, $0.05 in Q4 2025, and -$0.12 in Q3 2025.